Sees FY25 adjusted EBITDA of $270M to $320M vs. $176.9M in FY24, reflecting an Adjusted EBITDA margin of 12% to 13%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers reports Q4 EPS 11c, consensus 22c
- Hims & Hers sees Q1 adjusted EBITDA $55M-$65M
- Hims and Hers Health options imply 17.3% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, February 24, 2025
- Hims & Hers Health: Navigating Uncertainty with At-Home Lab Testing Expansion